Document ID: chunk:federal_register_of_legislation:F2021C00904:reg:9:p8
Version: federal_register_of_legislation:F2021C00904
Segment Type: reg
Provision Reference: reg 9 (pt 8/11)
Character Range: 24044–27100

having hypothyroidism or Hashimoto's thyroiditis with hypothyroidism for at least two years within the ten years before the clinical worsening of ischaemic heart disease;
(59)      inhaling or having cutaneous contact with Otto fuel or explosive products containing nitroglycerine, nitroglycol, trinitrotoluene or dinitrotoluene, where the last inhalation or cutaneous contact occurred not more than 14 days before the clinical worsening of ischaemic heart disease;
(60)      having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the heart at least one year before the clinical worsening of ischaemic heart disease;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
(61)      undergoing a course of therapeutic radiation for cancer, where the heart was in the field of radiation, before the clinical worsening of ischaemic heart disease;
(62)      having a clinically significant disorder of mental health as specified for at least the five years before the clinical worsening of ischaemic heart disease;
Note: clinically significant disorder of mental health as specified is defined in the Schedule 1 - Dictionary.
(63)      using a combined oral contraceptive pill  for at least the 21 days before the clinical worsening of ischaemic heart disease;
(64)      being treated with a drug, or a drug from a class of drugs, from Specified List 1 of drugs, where that drug cannot be ceased or substituted, at the time of the clinical worsening of ischaemic heart disease;
Note: Specified List 1 of drugs is defined in the Schedule 1 - Dictionary.
(65)      using a drug belonging to the non-steroidal anti-inflammatory class of drugs, excluding aspirin, paracetamol and topical non-steroidal anti-inflammatory drugs, for a continuous period of at least three days before the clinical worsening of ischaemic heart disease, where the last dose of the drug within that period was taken within the seven days before the clinical worsening of ischaemic heart disease;
(66)      having bilateral orchiectomy before the clinical worsening of ischaemic heart disease;
(67)      having antiandrogen therapy as specified for at least the seven days before the clinical worsening of ischaemic heart disease;
Note: antiandrogen therapy as specified is defined in the Schedule 1 - Dictionary.
(68)      inhaling, ingesting or having cutaneous contact with the phenoxy acid herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) or 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), for a cumulative period of at least 1 000 hours within a consecutive period of ten years, before the clinical worsening of ischaemic heart disease, where the first exposure occurred at least five years before the clinical worsening of ischaemic heart disease, and where that exposure has ceased, the clinical worsening of ischaemic heart disease occurred within 25 years after cessation;
(69)      inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD), for a